Catalog record · Compliance & Regulatory
Stage as of source date not established · historical report, not live reconfirmation.
Novo Nordisk structured regulatory-document authoring
Primary workflow source. A named organization's workflow supported by a reviewed primary source. Stage is reported separately; this label does not establish measured outcomes or independent validation.
Last researched Oct 26, 2026. Source access and reported stage are recorded below; deployment evidence does not establish ROI.
What the research supports
In-house AI authoring creates structured trial, study and stability documents using defined content rules.
- Reported stage
- Production
- Technology
- Other supported technology
- Business function
- Back Office
- Impact (legacy label)
- Not labeled
- Catalog date · unconfirmed
- Not reported
- Imported
- Oct 29, 2026
- Last researched
- Oct 26, 2026
Measures & evidence
Approximately 70% faster document production
Original metric claim
Measurement window not disclosed
Scope, baseline & source
- Scope / denominator
- Measurement population / workflow scope not disclosed
- Baseline
- Not disclosed in this account
- Claim basis
- Issuer slide; methodology and scope not supplied.
Source-reported claim; methodology, baseline and independent validation may be undisclosed. Inspect the research dossier.
Original prose retained. A single comparable value or unit has not been established.
Read dossier source ↗Exact claim-to-source location has not been mapped. This link belongs to the research dossier.
Measures retain their original currency, scope and period. Capacity, adoption and forecasts are not realized cash savings.
A separately curated evidence brief covers this initiative.
90%
less clinical-study-report writing time, reported in a vendor case study
Deployed workflow; measurement period not disclosed
Scope, baseline & source
- Scope / denominator
- Clinical-study-report writing in NovoScribe; human review and approval are subsequent workflow stages.
- Baseline
- Not disclosed in this account
- Claim basis
- Vendor case study
Supplier-hosted customer claim with no sample, error rate or costing method. Minutes-to-generate headlines concern document production, not the complete clinical/regulatory approval cycle or drug discovery. Legacy-data integrations required substantial work.
Read claim source ↗Measures retain their original currency, scope and period. Capacity, adoption and forecasts are not realized cash savings.
Documented vendor relationships
No vendor relationship has been linked to this specific workflow in the curated overlay. This does not mean it was built without vendors.
See the company’s documented relationshipsDeployment evidence & limits
Capital Markets Day slide labels document automation as value generated today and full submission-package automation as potential expansion. Status date not established.
Stage is as reported in the cited evidence. Current operating status has not been independently reconfirmed; the research date is an editorial review date.
The one-day submission-package readiness item sits under potential expansion, not achieved deployment. 2024 investor deck; exact publication day and underlying AI architecture not recorded. Regulatory acceptance, human review time and error rates must be tested in finance; full package automation is not established.
Potential FS application · inferred
Inferred: Regulatory-reporting teams: draft repeatable risk-model validation narratives and reporting annexes from reconciled tables.
Controlled structure and content rules combine verified data with recurring document sections.
Original industry: Pharmaceuticals and biotechnology. Transfer limits: Regulatory acceptance, human review time and error rates must be tested in finance; full package automation is not established.
Recorded dependencies
- Traceable source data and approved document/control schemas
- Qualified human review and local testing of accuracy, omissions and full workflow effort
Source register
- Data science & AI — Capital Markets Day 2024 break-out sessionnovonordisk.com · opens in a new tab
Novo Nordisk · issuer · full-text · Publication date not recorded
Research lanes: health_life_sciences · Batch global-discovery-2026-10-26. Coverage and remaining gaps